SINGAPORE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it secures non-dilutive investment for its subsidiary, LongevityBank Pte Ltd (“LongevityBank”) from ICH Capita ...

Core Insights - CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing affordable donor-derived cell-based immunotherapies for various cancers, including blood and solid tumors [1][3] - Executive Chairman Peter Choo has increased his shareholding in the company, now owning 21.95% of total outstanding shares, indicating his confidence in the company's potential [1][2] Company Overview - CytoMed was incorporated in 2018 and spun off from Singapore's Agency for Science, Technology and Research (A*STAR) [3] - The company specializes in proprietary technologies, including gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, aimed at creating novel allogeneic immunotherapies for cancer treatment [3] Market Context - There is rising investor interest in biotherapeutics in Asia, particularly in China, which presents unique opportunities for innovation and cost-competitive patient access [2] - The expanding healthcare and medical travel ecosystem in Southeast Asia, along with increasing healthcare costs in the West, further enhances the market potential for CytoMed's offerings [2]

Core Insights - CytoMed Therapeutics Limited has successfully completed dose level 1 of its first-in-human Phase I dose-escalation clinical trial (ANGELICA Trial) for late-stage cancer patients and plans to start dose level 2 in Q3 2025 [1][2] - The ANGELICA Trial is focused on evaluating the safety and tolerability of allogeneic NKG2DL-targeting CAR gamma delta T cells (CTM-N2D) for various cancer indications, including advanced solid and hematological malignancies [2] - CTM-N2D utilizes gamma delta T cells from healthy donors, which can be infused into patients without the need for donor-patient compatibility matching, differentiating it from conventional CAR-αβ T cell therapies [3][4] Company Overview - CytoMed was incorporated in 2018 and spun off from Singapore's Agency for Science, Technology and Research (A*STAR), focusing on developing novel cell-based allogeneic immunotherapies for cancer treatment [5] - The company aims to address the clinical limitations and commercial challenges of existing CAR-T therapies, particularly in treating solid tumors [5]